Hansoh Pharmaceutical Group

The phase‑III ARTEMIS‑011 study in China showed that Risvutatug Rezetecan (Ris‑Rez) statistically significantly improved progression‑free survival versus chemotherapy in relapsed osteosarcoma. Secondary endpoints, including overall survival, showed consistent benefits, and the safety profile was in line with previous findings with no new safety signals. Hansoh will use the data for a regulatory submission in China. » Más en de.investing.com

The Phase-III ARTEMIS-008 study of risvutatug rezetecan conducted in China met its primary endpoint, showing a statistically significant improvement in overall survival versus standard therapy with topotecan. Key secondary endpoints, including progression-free survival, were also positive, and the safety profile was consistent with previous findings with no new signals. Hansoh Pharma will use the data for a regulatory submission in China; GSK holds exclusive rights outside mainland China, Hong Kong, Macau and Taiwan and is conducting a global Phase-III study with regulatory-relevant data expected next year. » Más en de.investing.com

Hansoh Pharmaceutical's shares plunged 5.4% on Tuesday to HK$38.06, hitting the lowest level since Jan. 7. The move followed the announcement of a zero-coupon convertible bond of HK$4.68 billion maturing in 2033, convertible into 81.55 million new shares (about 1.33% of the enlarged share capital). The company said it will invest the proceeds in R&D for oncology, the central nervous system, and metabolic and autoimmune diseases, but the conversion feature sparked investor concerns about dilution. » Más en de.investing.com

Hansoh Pharmaceutical's shares jumped about 70%, lifting founder Zhong Huijuan's net worth to $19.7 billion as investor optimism around its new drug candidates grows. In October Hansoh signed a $1.5 billion licensing pact with Roche that includes an $80 million upfront payment, up to $1.45 billion in milestones and future royalties. The company has struck six licensing deals since 2020 with major pharma partners and reported H1 2025 sales of 7.4 billion yuan and net profit of 3.1 billion yuan. Risks include low global drug approval rates and potential regulatory or trade headwinds, but analysts see further partnership opportunities in oncology, immunology and metabolism. » Más en forbes.com

According to Macquarie, the recent rally in Chinese biotech stocks was too rapid and focused mainly on small caps, while the environment for biopharma companies in China remains challenging. Macquarie now recommends Hansoh as its preferred investment, followed by BeOne and Akeso, and sees clinical CROs as potential beneficiaries. Investors are cautioned that most licensing deals by Chinese firms offer little long-term value and that many products in development are likely to fail. » Más en de.investing.com